

Acknowledgments

The authors thank the more than 50,000 women who took part in this research. The genotyping and analysis of this study, and the conduct of the SEARCH study, was funded by Cancer Research UK. DFE is a Principal Research Fellow of CR-UK and PDPP is a CR-UK Senior Clinical Research Fellow. During this research BAJP held a CR-UK Gibb fellowship. We thank Nuno Barbosa-Morais for bioinformatics advice, and Craig Luccarini, Blanca Vázquez Álvarez and Melanie Maranian for assistance with the genotyping, and Pat Hamilton for administrative help. We thank the East Anglian Cancer Registration and Information Centre (ECRIC) for access to data for the Search study. We also acknowledge the technical assistance and infrastructural support of many talented Perlegen Sciences employees. We thank Adrian Ibrahim from Cancer Research Technology and Marion Eaves from the University of Cambridge for their assistance. The resequencing of FGFR2 was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, U.S. Department of Health and Human Services. We thank Rebecca A. Hardy, Marbin A. Pineda, and Felecia Mann for laboratory assistance and William Rowe and Richard P. Finney for programming assistance. EPIC-Norfolk is supported by research programme grant funding from Cancer Research UK and the Medical Research Council with additional support from the Stroke Association, British Heart Foundation, Department of Health, Research into Ageing and Academy of Medical Sciences. The Multiethnic Cohort Study was supported by National Cancer Institute grants CA63464 (BEH) and CA54281 (LNK). The British Breast Cancer study was funded by Cancer Research UK and Breakthrough Breast Cancer. The Familial Breast Cancer Study is funded by Cancer Research UK and families are recruited by the Breast Cancer Susceptibility Collaboration (UK). The ABCFS was funded by the National Health and Medical Research Council, the Victorian Health Promotion Foundation, the New South Wales Cancer Council, and as part of the Breast Cancer Family Registry (BCFR) funded by the National Cancer Institute (USA) under RFA # CA-95-003. kConFab is supported by the National Breast Cancer Foundation, the National Health and Medical Research Council of Australia, and the Cancer Councils of Queensland, New South Wales, Western Australia, South Australia, and Victoria. We thank kConFab nurses, staff of the Familial Cancer Clinics, Heather Thorne, Eveline Niedermayr, Helene Holland and Gillian Dite for their contribution to the kConFab and ABCFS studies, and the Clinical Follow Up Study of kConFab (funded by the National Health and Medical Research Council of Australia (NHMRC grants 145684 and 288704)) for supplying some data. The AOCS, which provided control samples only for the study, was supported by the U.S. Army Medical Research and Material Command under DAMD17-01-1-0729, the Cancer Council Tasmania and Cancer Foundation of Western Australia. The AOCS Management Group members include David Bowtell, Adele Green, Penny Webb, Anna DeFazio and Dorota Gertig. The genotyping and analysis were supported by grants from the National Health and Medical Research Council (NHMRC). ABS is funded by an NHMRC Career Development Award, and GC-T and JLH are NHMRC Senior Principal Research Fellows. The Copenhagen Breast Cancer Study and The Copenhagen General Population Study were supported by Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, Copenhagen County and Herlev University Hospital. The Polish Breast Cancer Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human

Services, USA. The authors would like to thank Drs. Neonila Szeszenia-Dabrowska and Beata Peplonska of the Nofer Institute of Occupational Medicine (Lodz, Poland) and Witold Zatonski of the M.Sklodowska-Curie Institute of Oncology and Cancer Center (Warsaw, Poland) for their contribution to the Polish Breast Cancer Study. The Helsinki Breast Cancer Study was supported by the Academy of Finland (110663), Helsinki University Central Hospital Research Fund, the Sigrid Juselius Fund and the Finnish Cancer Society. We thank Drs. Kirsimari Aaltonen, Carl Blomqvist, Kristiina Aittomäki and Karl von Smitten for their kind help in sample and data collection. The Nurses Health Study is supported by NIH grants CA65725 (to DJH) and CA87969 (to SEH). We wish to thank Pati Soule and Hardeep Ranu of the DF/HCC Polymorphism Detection Core for sample handling and genotyping. The Singapore and Swedish Breast Cancer Study (SASBAC) was supported by funding from the Agency for Science, Technology and Research of Singapore (ASTAR), United States National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. We thank Johann H. Karstens, Michael Bremer, Alexander Scharf, Peter Hillemanns and Christof Sohn for their support of the HBCS study at Hannover Medical School. The LUMC study was supported by ORIGO cohort study group members J. Blom, E. Krol-Warmerdam, M. Vreeswijk. The United States Radiologic Technologists (USRT) study was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, the National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. We thank Diane Kampa for field co-ordination of USRT genetic studies. The Spanish National Cancer Centre Study was partially supported by the Genome Spain Foundation. We thank Emilio Gonzalez and Charo Alonso for their technical support and Dr Arias, Dr Ruibal, Dr Zamora and Dr Palacios for supplying us the samples. The Melbourne Collaborative Cohort Study (MCCS) recruitment was funded by VicHealth and The Cancer Council Victoria (TCCV). Its ongoing infrastructure has been funded by TCCV and its continuing follow up by TCCV and grants from the National Health and Medical Research Council (209057, 396414). The GENICA study was supported by the German Human Genome Project and funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114. Genotyping analyses were supported by Robert Bosch Foundation of Medical Research, Stuttgart, Germany. We thank Beate Pesch for the patient recruitment and collection of epidemiologic data. The Sheffield Breast Cancer Study was supported by Yorkshire Cancer Research and the Breast Cancer Campaign. We thank Sue Higham, Sabapathy Balasubramanian, Helen Cramp, Dan Connley, Saeed Raffi and Mark Meuth. The Mayo Breast Cancer Study was supported by NIH/NCI Breast Cancer SPORE P50 CA116201, NIH P01 CA82267 and W81XWH-04-1-0588. ELG is funded by a Cancer Research Fellowship from the Fraternal Order of Eagles. The Kuopio Breast Cancer Project was supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Finnish Cancer Organisations and Cancer Fund of North Savo. We are grateful to Eija Myöhänen for technical assistance.